Foghorn Therapeutics

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Company presentation and fireside chat on April 11th at 11:45 a.m. ET Company presentation and fireside chat on April 11th at 11:45 a.m. ET

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen's 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2023, in San Diego, California.

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended September 30, 2023. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the dose escalation and expansion study of FHD-286 in metastatic uveal melanoma (mUM) will be presented at the ESMO Congress 2023, to be held October 20–24 in Madrid, Spain.

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Denali Therapeutics

Seres Therapeutics

Moderna

Omega Therapeutics

Sana Biotechnology

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced the first patient has been dosed in the Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myelogenous leukemia (AML).

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology, called "gene traffic control," aims to regulate gene expression by targeting chromatin in the chromatin gene regulatory system. The company faced setbacks with clinical holds and program cancellations, including a patient death and poor phase 1 data for their uveal melanoma program.

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.66 per share a year ago.

News for Foghorn Therapeutics Stock (FHTX)